Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study

Yuichi Kojima,Toshihisa Takeuchi,Makoto Sanomura,Ken Higashino,Keishi Kojima,Kenji Fukumoto,Kou Takata,Hiroki Sakamoto,Masahiro Sakaguchi,Kazunari Tominaga,Kazuhide Higuchi

Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study

2018

Yuichi Kojima
Toshihisa Takeuchi
Makoto Sanomura
Ken Higashino
Keishi Kojima
Kenji Fukumoto
Kou Takata
Hiroki Sakamoto
Masahiro Sakaguchi
Kazunari Tominaga
Kazuhide Higuchi

Background/Aim: The long-term administration of proton pump inhibitors (PPIs) is useful for preventing recurrent reflux esophagitis. On the other hand, several ad

Keywords:

Vonoprazan
Prospective cohort study
Reflux esophagitis
Endocrinology
Gastroenterology
Potassium
Cross-sectional study
2-Pyridinylmethylsulfinylbenzimidazoles
Diabetes mellitus
Internal medicine
Medicine
Proton-pump inhibitor
Gastritis
Esophagitis
Gastrin
Atrophic gastritis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations